fibrosis

February 6, 2023

Gut microbiota and lung fibrosis

Microorganisms residing in the gut influence the severity of lung fibrosis in mouse models, suggesting that modifying the gut microbiota may offer therapeutic benefit for patients.

By Leigh MacMillan
October 20, 2022

New target for lung fibrosis

Blocking thromboxane-prostanoid receptor signaling protected animals from lung fibrosis in preclinical models, suggesting a new treatment for IPF — a chronic, progressive lung disorder that often kills within 3-5 years of diagnosis.

By Leigh MacMillan
July 30, 2020

Protein study may be key to treating fibrotic diseases

A protein linked to amyotrophic lateral sclerosis (ALS), a progressive neurological disease that causes muscle weakness, may be a key to treating fibrotic disease of the kidneys and other organs, researchers at Vanderbilt University Medical Center reported recently.

By Bill Snyder
August 8, 2019

New window on fibrosis

A previously unrecognized role for a cell surface receptor may open new therapeutic options for the treatment of fibrotic diseases.

By Bill Snyder
March 28, 2019

Cardiac dysfunction in DMD

The protein MMP7 is elevated in blood from patients with Duchenne muscular dystrophy who have cardiac dysfunction, suggesting that it may be a biomarker for heart disease severity.

By Leigh MacMillan
January 31, 2019

New target for chronic kidney disease

Preventing the formation of secretory structures that promote scarring in the kidney could offer new therapeutic options for a disease that affects millions of people worldwide.

By Leigh MacMillan